References
- RoweASMahbubaniPSBucklinMHClarkCTHamiltonLAActivated prothrombin complex concentrate versus plasma for reversal of warfarin-associated hemorrhagePharmacotherapy201636111132113727726162
- MarinoKKSantiagoRADewRB3rdManagement of dabigatran-associated bleeding with two doses of idarucizumab plus hemodialysisPharmacotherapy20163610e160e16527581709
- YuHCChanTYCritchleyJAWooKSFactors determining the maintenance dose of warfarin in Chinese patientsQJM19968921271358729554
- LiTChangCYJinDYLinPJKhvorovaAStaffordDWIdentification of the gene for vitamin K epoxide reductaseNature2004427697454154414765195
- ObengAOKaszemacherTAbul-HusnNSImplementing algorithm-guided warfarin dosing in an ethnically diverse patient population using electronic health records and preemptive CYP2C9 and VKORC1 genetic testingClin Pharmacol Ther2016100542743027393744
- RostSFreginAIvaskeviciusVMutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2Nature2004427697453754114765194
- GoodstadtLPontingCPVitamin K epoxide reductase: homology, active site and catalytic mechanismTrends Biochem Sci200429628929215276181
- BodinLVerstuyftCTregouetDACytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivityBlood2005106113514015790782
- RiederMJReinerAPGageBFEffect of VKORC1 haplotypes on transcriptional regulation and warfarin doseN Engl J Med2005352222285229315930419
- YuanHYChenJJLeeMMA novel functional VKORC1 promoter polymorphism is associated with inter-individual and interethnic differences in warfarin sensitivityHum Mol Genet200514131745175115888487
- Sullivan-KloseTHGhanayemBIBellDAThe role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphismPharmacogenetics1996643413498873220
- StubbinsMJHarriesLWSmithGTarbitMHWolfCRGenetic analysis of the human cytochrome P450 CYP2C9 locusPharmacogenetics1996654294398946475
- D’AndreaGD’AmbrosioRLDi PernaPA polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarinBlood2005105264564915358623
- HartRVeenstraDLBoudreauDMRothJAImpact of body mass index and genetics on warfarin major bleeding outcomes in a community settingAm J Med2016130222222827593608
- JohnsonJAGongLWhirl-CarrilloMClinical Pharmacogenetics Implementation ConsortiumClinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosingClin Pharmacol Ther201190462562921900891
- TakahashiHWilkinsonGRNutescuEADifferent contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-AmericansPharmacogenet Genomics200616210111016424822
- MoonHWNohJYunYMThe effect of CYP2C9, VKORC1 genotypes and old age on warfarin pharmacologic sensitivity in Korean patients with thromboembolic diseaseAnn Clin Lab Sci201141322923522075505
- VerstuyftCDelavenneXRousseauAA pharmacokinetic-pharmacodynamic model for predicting the impact of CYP2C9 and VKORC1 polymorphisms on fluindione and acenocoumarol during induction therapyClin Pharmacokinet2012511415322149257
- KovacMKMaslacARRakicevicLBRadojkovicDPThe c.-1639G>A polymorphism of the VKORC1 gene in Serbian population: retrospective study of the variability in response to oral anticoagulant therapyBlood Coagul Fibrinolysis201021655856320581661
- ZhengWMcLerranDFRollandBAssociation between body-mass index and risk of death in more than 1 million AsiansN Engl J Med2011364871972921345101